-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Is Mabpharm Limited (HKG:2181) Popular Amongst Insiders?
Is Mabpharm Limited (HKG:2181) Popular Amongst Insiders?
If you want to know who really controls Mabpharm Limited (HKG:2181), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.
Mabpharm is a smaller company with a market capitalization of HK$2.9b, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have not yet purchased shares. We can zoom in on the different ownership groups, to learn more about Mabpharm.
View our latest analysis for Mabpharm
SEHK:2181 Ownership Breakdown July 7th 2022What Does The Lack Of Institutional Ownership Tell Us About Mabpharm?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.
There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. Alternatively, there might be something about the company that has kept institutional investors away. Mabpharm's earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely.
SEHK:2181 Earnings and Revenue Growth July 7th 2022We note that hedge funds don't have a meaningful investment in Mabpharm. Looking at our data, we can see that the largest shareholder is Jianjun Guo with 50% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 18% and 5.2%, of the shares outstanding, respectively.
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Mabpharm
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our most recent data indicates that insiders own a reasonable proportion of Mabpharm Limited. It has a market capitalization of just HK$2.9b, and insiders have HK$1.5b worth of shares in their own names. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 23% stake in Mabpharm. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
Private equity firms hold a 23% stake in Mabpharm. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
Private Company Ownership
Our data indicates that Private Companies hold 4.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Mabpharm has 3 warning signs (and 2 which can't be ignored) we think you should know about.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道誰真正控制了Mabpharm Limited(HKG:2181),那麼你必須看看它的股票登記處的構成。內部人士通常持有大量較年輕、規模較小的公司,而大公司往往有機構作為股東。我非常希望看到至少有一點內部人持股。正如查理·芒格所説,給我看激勵措施,我就會告訴你結果。
Mabpharm是一家規模較小的公司,市值為29億港元,因此它可能仍在許多機構投資者的雷達下飛行。我們對公司所有權的分析顯示,機構投資者尚未購買股票。我們可以放大不同的所有權組,瞭解更多關於Mabpharm的信息。
查看我們對Mabpharm的最新分析
聯交所:2181擁有權分類2022年7月7日機構所有權的缺失告訴了我們關於Mabpharm的什麼?
交易不太活躍的小公司往往缺乏機構投資者,但大公司沒有機構投資者的情況較少。
為什麼沒有機構持有一家公司的股票,可能有各種原因。通常情況下,新上市的小型公司不會引起基金經理太多關注,因為大型基金管理公司不可能在該公司建立有意義的頭寸。或者,該公司可能有某些方面讓機構投資者望而卻步。Mabpharm的盈利和營收記錄(見下文)對機構投資者來説可能並不令人信服--或者他們可能只是沒有密切關注這項業務。
聯交所:2181盈利及收入增長2022年7月7日我們注意到,對衝基金沒有對Mabpharm進行有意義的投資。看看我們的數據,我們可以看到,第一大股東是郭建軍,持有50%的流通股。與此同時,第二大和第三大股東分別持有流通股的18%和5.2%。
在進一步挖掘後,我們發現,前兩名股東共同控制着公司一半以上的股份,這意味着他們擁有相當大的權力來影響公司的決策。
雖然研究一家公司的機構持股可以增加你的研究價值,但研究分析師的建議以更深入地瞭解一隻股票的預期表現也是一個很好的做法。我們的信息顯示,分析師沒有對該股進行任何報道,因此它可能鮮為人知。
Mabpharm的內部人士所有權
儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層管理企業,但首席執行官將向董事會負責,即使他或她是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們的最新數據顯示,內部人士持有Mabpharm Limited相當比例的股份。它的市值只有29億港元,內部人士以自己的名義持有價值15億港元的股票。我們會説,這表明了與股東的一致,但值得注意的是,該公司仍相當小;一些內部人士可能創建了這家企業。你可以點擊這裏,看看這些內部人士是一直在買入還是賣出。
一般公有制
公眾通常是個人投資者,他們持有Mabpharm 23%的股份。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私募股權所有權
私募股權公司持有Mabpharm 23%的股份。這表明,他們可以在關鍵的政策決策中發揮影響力。一些投資者可能會因此而受到鼓舞,因為私人股本有時能夠鼓勵有助於市場看到公司價值的策略。或者,這些持有者可能會在投資上市後退出。
私營公司所有權
我們的數據顯示,私營公司持有該公司4.0%的股份。或許有必要對此進行更深入的研究。如果關聯方,如內部人士,對這些私營公司中的一家有利害關係,則應在年報中披露。私營公司也可能對該公司擁有戰略利益。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。以風險為例-Mabpharm擁有3個警示標誌(和2個不容忽視的問題)我們認為你應該知道。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費令人感興趣的公司名單,有強勁的財務數據支持。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧